title: Factors affecting penetration of retrograde coronary venous injections into normal and ischemic canine myocardium: assessment by contrast echocardiography and digital angiography.
abstract: Ths experimental study described myocardial echo contrast enhancement through coronary venous injections. Retrograde administration of renografin was performed in 15 closed-chest dogs. Two-dimensional echocardiography was used to study myocardial echo contrast enhancement before and after coronary artery occlusion. Digital subtraction venography was used to assess delivery, drainage and shunting of the retrograde injectate. Systolic/diastolic blood pressure in the great cardiac vein measured 7 +/- 3/1 +/- 0.6 mm Hg and increased to 29 +/- 11/5 +/- 3 after coronary sinus occlusion and to 55 +/- 2.3/15 +/- 12 mm Hg during coronary sinus contrast injection. Myocardial contrast echo appearance in a midpapillary left ventricular short axis cross-section was limited to the anteroseptal region, extending to 28.4 +/- 11.3% of the section circumference after great cardiac vein injections and 35.3 +/- 17% after coronary sinus injections (difference NS). After occlusion of the left anterior descending coronary artery, great cardiac vein contrast injections resulted in opacification of 36.6 +/- 9.7% of the section circumference (N.S. vs preocclusion control) and opacified most, but not all asynergic segments. After occlusion of the circumflex coronary artery, myocardial echo contrast uptake was restricted to the septum and the anterior wall. The ischemic and asynergic posterolateral myocardial segments were not opacified. Digital subtraction coronary venography revealed rapid drainage of retrogradely injected contrast to the right atrium, in spite of coronary sinus balloon occlusion via venovenous anastomoses. Retrograde coronary venous contrast injections may help define myocardial regions which are accessible with retrograde coronary venous interventions.
authors.affiliation: Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
authors.forename: C
authors.initials: C
authors.lastname: Punzengruber
authors.forename: G
authors.initials: G
authors.lastname: Maurer
authors.forename: B L
authors.initials: BL
authors.lastname: Chang
authors.forename: K
authors.initials: K
authors.lastname: Ong
authors.forename: S
authors.initials: S
authors.lastname: Meerbaum
authors.forename: E
authors.initials: E
authors.lastname: Corday
mesh_terms: D015901:Angiography, Digital Subtraction / Q000379:methods*; D000818:Animals; D006328:Cardiac Catheterization / Q000379:methods*; D003287:Contrast Media; D003331:Coronary Vessels / Q000187:drug effects*; D003973:Diatrizoate / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003974:Diatrizoate Meglumine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004285:Dogs; D004338:Drug Combinations / Q000008:administration & dosage / Q000493:pharmacokinetics; D004452:Echocardiography / Q000379:methods*; D007090:Image Interpretation, Computer-Assisted; D007275:Injections, Intravenous; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000175:diagnosis; D009206:Myocardium / Q000473:pathology; D014690:Venous Pressure / Q000187:drug effects*
chemical_list: D003287:Contrast Media; D004338:Drug Combinations; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision